Skip to main content
Journal Article

Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.

Critical care (London, England) (2005) 9(5)
ISSN: 1466609X
6Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Cite

CITATION STYLE

APA

Rondon, E., & Venkataraman, R. (2005). Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels. Critical Care (London, England), 9(5).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free